Skip to main content
. 2019 Mar 27;10:562. doi: 10.3389/fimmu.2019.00562

Figure 2.

Figure 2

Fc3aV binds to FcγRIIIAV158 with exquisite selectivity (A) Binding activities of ICs (10 μg/ml), formed by mixing antibodies with F(ab′)2 anti-hIgG F(ab′)2-PE, to human FcγRs expressed by transfectant CHO cell measured by FACS, when antibodies are: isotype control (red), wt Trastuzumab (orange), Trastuzumab-Fc3aV (sky blue), and Trastuzumab-Fc5 (purple). (B,C) Binding activities of ICs on human neutrophils (B) or NK cells (C); immune complexes were formed and used at the same concentration as in (A). Left panels: Expression level of FcγRs on neutrophils activated by IFN-γ (B) or NK cells (C) detected by the respective anti-FcγR antibodies conjugated to APC; Right panels: Binding of ICs formed by wt or Fc3aV Trastuzumab, onto neutrophils or NK cells, respectively. Representative data of three independent experiments are shown.